ALSA Ventures

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Axovia Therapeutics is focused on developing transformative gene therapies aimed at addressing ciliopathies, a group of rare genetic disorders that can lead to severe health issues, including blindness. The company utilizes Adeno-Associated Virus (AAV) technology to target the underlying causes of these conditions, facilitating earlier diagnosis and treatment. By concentrating on the crucial aspects of ciliopathies, Axovia seeks to improve the lives of patients, their families, and caregivers affected by these debilitating diseases.

Vantage Biosciences is a biotechnology company focused on developing an innovative oral therapy aimed at addressing diabetic eye diseases. The company's platform targets the underlying causes of vision loss associated with diabetes by offering a novel treatment for inflammatory conditions. This approach seeks to alleviate the significant burden of diabetic eye diseases, ultimately helping patients to protect and preserve their vision. Through its research and development efforts, Vantage Biosciences aims to provide effective solutions for individuals affected by these challenging health issues.

Jatri is a rapidly growing technology company based in Bangladesh that aims to provide reliable transportation solutions accessible to everyone. The company has developed a mobility-as-a-service platform that enhances the reliability and quality of bus systems, enabling commuters to travel more efficiently. Jatri's platform facilitates bus ticketing and tracking, encouraging a shift from private vehicle ownership to a more equitable and accessible public transportation system. By streamlining the journey experience for users, Jatri supports drivers in delivering dependable transport services to commuters, ultimately promoting smarter mobility options within urban environments.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Promatix is a biotechnology company focused on the development of innovative therapeutics, particularly in the field of cancer treatment. The company leverages a multi-omics platform that integrates proteomic, genomic, and transcriptomic data to discover and validate new therapeutic targets. By utilizing their TxPro technology, Promatix identifies and assesses novel drug targets at the protein level through differential protein expression analysis in both diseased and normal tissues. This approach enables Promatix to support medical companies in the discovery and validation of drug targets, enhancing the pipeline for potential cancer therapies.

Montis Biosciences is a biotechnology company founded in 2020 and based in Meise, Belgium. The company focuses on developing innovative immune-oncology therapeutics that address the intersection of vascular dysfunction and immune suppression in the treatment of solid tumors. Montis Biosciences has created a proprietary target screening and assay platform aimed at modulating the interactions between tumor endothelial cells and perivascular macrophages. This research provides valuable insights into the cellular dynamics of these interactions, enabling the development of novel therapeutic strategies to enhance immune responses against various tumors.